Japanese regulatory agency approves Aegerion Pharmaceuticals' JUXTAPID

Japan's Ministry of Health, Labor & Welfare approved Aegerion Pharmaceuticals Inc.'s (Nasdaq: AEGR) JUXTAPID to treat homozygous familial hypercholesterolemia. The stock price rose 57 cents to close at $3.06.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.